SHARE

Sanofi to acquire Vigil Neuroscience in $470m deal

Sanofi will acquire clinical-stage biotech firm Vigil Neuroscience to strengthen its neurological pipeline through an Alzheimer’s drug. The deal includes $8 per share for Vigil shareholders, plus a potential $2 per share contingent value right.

Certification Note

Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.